Notice: Users may be experiencing issues with displaying some pages on stanfordhealthcare.org. We are working closely with our technical teams to resolve the issue as quickly as possible. Thank you for your patience.
New to MyHealth?
Manage Your Care From Anywhere.
Access your health information from any device with MyHealth. ÌýYou can message your clinic, view lab results, schedule an appointment, and pay your bill.
ALREADY HAVE AN ACCESS CODE?
DON'T HAVE AN ACCESS CODE?
NEED MORE DETAILS?
MyHealth for Mobile
WELCOME BACK
or
BASECAMP-1: Leveraging human leukocyte antigen (HLA) loss of heterozygosity (LOH) in solid tumors by next-generation sequencing (NGS) to identify patients with relapsed solid tumor for future logic-gated Tmod CAR T-cell therapy
ÌÇÐÄ´«Ã½
BASECAMP-1: Leveraging human leukocyte antigen (HLA) loss of heterozygosity (LOH) in solid tumors by next-generation sequencing (NGS) to identify patients with relapsed solid tumor for future logic-gated Tmod CAR T-cell therapy Simeone, D. M., Hecht, J., Patel, S., Morelli, M., Kirtane, K., Borad, M. J., Maus, M., Sunwoo, J. B., Welling, T., Lin, Y., Garon, E. B., Kopetz, S., Locke, F. L., Liechty, K. B., Lozac'hmeur, A., Beutner, K., Ng, E., Go, W. Y., Maloney, D. G., Molina, J. R. LIPPINCOTT WILLIAMS & WILKINS. 2022View details for